WESTLAKE VILLAGE, Calif., March 28, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, outlines the company’s growth strategy and continued clinical progress of its broad immuno-dermatology pipeline during today’s Investor Day in Boston, MA at 10:30 a.m. EST.
The meeting features presentations followed by a Q&A session led by Arcutis executives, Frank Watanabe, President and Chief Executive Officer; Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer; Ken Lock, Chief Commercial Officer; and Scott Burrows, Chief Financial Officer.
“This year will be transformational for Arcutis. We have the right strategy in place to build on our sustained track record of clinical execution, commercialize our first product, and partner with dermatologists to tackle some of the most persistent challenges in immune-mediated dermatological diseases and conditions,” said Frank Watanabe. “We look forward to continuing to advance the development of topical roflumilast across multiple potential indications, as well as building out our early therapeutic pipeline, with our investigational therapy for alopecia areata expected to enter the clinic later this year.”
The Investor Day will highlight multiple programs, illustrating the significant opportunity in Arcutis’ portfolio and its value-creating potential:
Long-Term Value Creation for Shareholders
Roflumilast Cream in Plaque Psoriasis
Roflumilast Cream in Atopic Dermatitis
Roflumilast Foam in Seborrheic Dermatitis & Scalp Psoriasis
A link to register for the event is available here. The event will also be simultaneously webcast at the “Events” section of the Company’s website, with the presentation made available at the start of the live webcast. An archived replay of the webcast will be available on the Arcutis website following the event.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, with one NDA under review with the FDA and three Phase 3 clinical data readouts anticipated by the end of 2022. The company’s lead program, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis of the body and scalp, atopic dermatitis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter.
This press release contains “forward-looking” statements. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, current and future commercialization activities and their potential success, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment, and potential market opportunities. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as our subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Amanda Sheldon, Head of Corporate Communications
Eric McIntyre, Head of Investor Relations